Antares Therapeutics applies a proprietary covalent discovery engine—including proprietary screening libraries, chemoproteomics, structure‑guided computational chemistry and machine‑learning tools—to identify challenging, high‑value oncology targets. The company will lead discovery work on a limited set of historically undruggable targets under a collaboration with Novartis while continuing to advance its owned and partnered portfolio of precision cancer and other serious‑disease medicines. Financially, the collaboration provided a $105 million upfront payment and the potential for up to $1.8 billion in additional milestone payments and tiered royalties if programs progress and commercialize. The partnership is intended to pair Antares’ discovery capabilities with Novartis’ development and global commercialization resources to accelerate translation of its science into therapies.

Total raised

$282M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2026